BioSpace

Biotech IPOs raise $7.5B as sector’s performance rally flattens

While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same period was muted, with most of the yearly gains for the U.S. biotech-specific index largely driven by the first half of 2026.

By BioSpace

1 min read
Biotech IPOs raise $7.5B as sector’s performance rally flattens
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights